Go Back

Akums Drugs & Pharmaceuticals Ltd the largest India-focused CDMO in terms of revenue, productio...

Posted: 03 Nov 2024

Akums Drugs & Pharmaceuticals Ltd the largest India-focused CDMO in terms of revenue, production capacity and clients served during the Financial Year 2023 (among CDMOs assessed by F&S) (Source: F&S Report). Research and Development 4 Research and Development (R&D) Units drives our continuous efforts in product development, ensuring innovative solutions. Pharmaceutical Manufacturer we are a pharmaceutical contract development and manufacturing organization (�CDMO�) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, we own the intellectual property for the manufacturing processes of several of our formulations, and our core business is focused on providing end-to-end product development and manufacturing solutions to our clients. Some of our other services include formulation research and development (�R&D�), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. Research & Development (R&D) and Quality Assurance Unwavering dedication to cutting-edge research and development, ensuring product efficacy and safety through stringent quality assurance measures. Quality Our customers can trust us to deliver quality products available in our industry. We are committed to providing only the quality products for our customers, every step of the way. We stand behind every product and service we provide. We are proud to be a company that puts quality first, and we will never waver in our quest for excellence. Delivery We understand the importance of reliability and punctuality in today's fast-paced business world and we are dedicated to working hard to ensure that our customers can always count on us for reliable delivery and service. When it comes to deliveries and services, our word is our bond and we will never let our customers down. Customer satisfaction is our top priority and are dedicated to delivering products that exceed expectations. Innovation We are constantly striving to improve our products by bringing innovation and creativity. Our success is due to our ability to provide the quality products to our customers. Every day is a new challenge and we are excited for all the new opportunities that come our way. Innovation is the lifeblood of our company and we will always strive to be the best in our business. Nutraceutical Manufacturer Akums meets the escalating demand for health and wellness products with expertise and precision. By translating nutraceutical concepts into tangible products, Akums empowers businesses to cater to the health-conscious consumer base. Its state-of-the-art manufacturing facilities and unwavering commitment to maintaining the highest quality standards ensure that the nutraceutical products produced are safe, effective, and aligned with consumer expectations. This vital role strengthens the health and wellness industry in India, fostering a culture of well-being and balanced living. API Manufacturer Following the acquisition of Parabolic Drugs by our Company in 2021, we entered the business of the manufacture and sale of key starting materials, intermediates and APIs, and acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an R&D centre in Barwala, Haryana. Details of our API units are set out below: Dera Bassi, Punjab: This unit is dedicated to the production of beta lactams and is equipped with six production blocks. With an annual capacity of 557.00 MT. This unit enables us to carry out complex multistep synthesis processes, meeting the high demand for beta lactam APIs. Lalru, Punjab: This unit is designed for the synthesis of a wide range of APIs spanning various therapy areas. This unit comprises three production blocks and has an annual production capacity of 180.00 MT. At this unit, we produce APIs across a broad spectrum of therapeutic categories. Barwala, Haryana: This unit is a specialized small-volume, high-potency API manufacturing unit with an annual production capacity of 0.38 MT. This unit features a kilo lab scale pilot plant for experimental and development purposes and is dedicated to handling high-potency APIs with a high degree of expertise.